



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :

A61J 3/07

A1

(11) International Publication Number:

WO 94/09746

(43) International Publication Date:

11 May 1994 (11.05.94)

(21) International Application Number: PCT/GB93/02271

(22) International Filing Date: 4 November 1993 (04.11.93)

(30) Priority data:

9223144.8

5 November 1992 (05.11.92) GB

(71) Applicant (for all designated States except US): R.P. SCHERER CORPORATION [US/US]; 2075 West Big Beaver Road, Troy, MI 48084 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only) : RASHID, Abdul [GB/GB]; 25 Camphill Avenue, Glasgow G41 3AU (GB). STEVENS, Howard, Norman, Ernest [GB/GB]; Ballyconachy, Balmaha Road, Drymen, Stirlingshire G63 0BX (GB). BINNS, Julie, Stephanie [GB/GB]; 10 Dryburgh Gardens, Glasgow G20 6BT (GB). MACKIE, James, Leonard [CA/CA]; 3350 Dolphin Court, Windsor, Ontario N8R 2G7 (CA).

(74) Agent: HORNER, Martin, Grenville; Cruikshank &amp; Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).

(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

## Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CONTROLLED RELEASE DEVICE

## (57) Abstract

A controlled release capsule comprises a male plug (2) formed of a water-swellaible hydrogel which is engaged within a neck portion (4) of a female body (6). The capsule is intended to deliver two dosages of pharmaceutically active material at different times. A water soluble cap (8) is fitted over mouth (14) of the body, and defines a first volume (9) containing a first unit dosage (10). A second unit dosage (12) is contained within a second volume (11) defined by the plug and the female body. When the capsule is swallowed by a patient, the cap dissolves quickly in the aqueous medium within the gastro-intestinal tract and releases the first dosage. The aqueous medium then comes into contact with the hydrogel plug which swells and becomes disengaged from the body, usually in the intestine, thereby releasing the second dosage a predetermined time after the first dosage.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CONTROLLED RELEASE DEVICETECHNICAL FIELD

The present invention relates to a controlled release capsule construction which comprises a male member engaged within a neck portion of a female body; the capsule including a water swellable material which swells so as to disengage the female body upon exposure of the capsule to an aqueous medium. The capsule is intended to release two dosages of pharmaceutically active materials at different times.

BACKGROUND

International patent specification W090/09168 discloses a device of this type which comprises a water swellable male plug engaged within a female body. A pharmaceutically active material is contained within the device. When the capsule is exposed to water, the male hydrogel plug swells and eventually disengages itself from the female body, thereby allowing the pharmaceutically active material contained within the device to be released. It has been found that the time taken to release the pharmaceutical material is predictable and reproducible, so that the device may be used to release pharmaceutically active material within the body of a patient after a predetermined time interval (e.g. 0.5 to 12 hours). This may, for example, be useful in the

- 2 -

treatment of medical conditions where it is desirable to administer a pharmaceutically active material to the patient sometime through the night while the patient is asleep, so as to provide a desired level of the drug in the patient in accordance with his needs, for example during the night or when he awakes. It may also be useful to allow dosing of materials at a predetermined point as the capsule passes through the gastro-intestinal tract, for example in the colon.

Patent specification W092/13521 (Alza Corporation) describes fluid-imbibing dispensing devices for delayed delivery of a pharmaceutically active agent, which include an expansion means which absorbs fluid from a surrounding environment. The dispensing device comprises a housing having first and second wall sections telescopically engaged with each other, particularly a capsule having a hollow cap and a hollow body; either the cap or the body is in the form of a male section fitted inside the open end of the other female section. The expansion means is contained within the device and expands as it absorbs fluid, forcing apart the two sections of the device. The expansion means may be a swellable polymer or an osmotic formulation which swells as it absorbs fluid. In order to allow fluid to come into contact with the expansion means contained within the device, one of the wall sections adjacent to the expansion means is fluid-permeable. After the sections are disengaged, fluid enters the device and

- 3 -

comes into contact with the active agent contained within the device, thereby dispensing the active agent into the fluid.

Conventional hard gelatin capsules are produced and filled in large numbers using high speed automatic machinery. Very often, the cap is pre-fitted to the capsule body during manufacture of the capsule. During filling, the filling machine removes the cap, fills the capsule with pharmaceutical material, and then replaces the cap in a manner such that the cap is locked onto the capsule body. Patent specification US 3,399,803 discloses a self-locking medicament capsule wherein the body has a groove near its open end and the cap has a corresponding ridge which snaps into the groove so as to lock the cap and body together. US 4,442,941 discloses a bayonet-type arrangement whereby a raised portion on the cap is engaged into a groove on the body. European patent specification 246604 also discloses a capsule body having a groove near its mouth for the purposes of preventing the capsule distorting from its cylindrical form, which may cause difficulty in fitting the cap onto the capsule body.

#### SUMMARY OF THE INVENTION

The present invention relates to a development of the capsule construction disclosed in WO90/09168 to allow sequential dosing of a patient at different times with the same or different pharmaceutically active materials.

Thus, the present invention provides a controlled release capsule which comprises a male member engaged within a female body;

the capsule including a water swellable material which swells so as to disengage the female body upon exposure of the capsule to an aqueous medium;

a cap of a water soluble material being fitted over a mouth of the female body and enclosing the male member such as to define a first volume containing a first unit dosage of a pharmaceutically active material; and

the female body and the male member defining a second volume containing a second unit dosage of a pharmaceutically active material.

In a preferred embodiment, the male member is a plug formed of said water-swellable material, such that as the plug swells it disengages from the female body. The plug is preferably formed of a water-swellable hydrogel, such as described in W090/C9168.

In view of the water-soluble nature of the cap (which is for example, formed of gelatin), the cap tends to dissolve very soon after administration to the patient thereby releasing the first dosage of pharmaceutically active material, usually in the patient's stomach. The first dosage of active material may thus become absorbed in the intestine.

Following dissolution of the cap, the hydrogel plug becomes exposed to the aqueous environment and begins to

- 5 -

swell. After a predetermined time interval, the hydrogel plug becomes disengaged, thereby releasing the second dosage of pharmaceutically active material at a further predetermined position in the patient's gastro-intestinal tract, such as the colon.

In an alternative embodiment, the water-soluble cap (and usually the capsule body also) is enteric coated so as to resist the acidic pH in the stomach and pass into the intestine. At the higher intestinal pH the enteric coat dissolves and allows dissolution of the cap and release of the first dosage of active material. The plug then hydrates and is expelled after a predetermined time (e.g. in the colon) to release the second dosage of active material.

For convenience, the first and second dosages of pharmaceutically active material are generally provided in solid form, such as a tablet; though other known dosage forms are possible, such as powders, granules, pellets, capsules and semi-solid material. The doses may be of the same or different active material. The first active material may be cast (e.g. as a molten liquid) into the end of the cap.

Although conventionally shaped round caps may be used, the cap is preferably substantially flattened compared to conventional caps so as to accommodate a tablet whilst retaining the compact nature of the capsule by minimising dead space in the first volume. The

- 6 -

flattened cap shape also reduces nesting and interlocking between free caps stored together in a filling machine. Interlocking is further minimised by making the caps thicker than conventional, or by enlarging the domed end of the cap. In addition, inwardly extending protrusions may be provided around the inside of the cap, so that a tablet can be clipped into place within the cap and retained there during assembly of the capsule. Such inward protrusions also function to act as stops limiting the extent to which the cap can be pushed onto the capsule body.

In one embodiment of the invention, the hydrogel plug is recessed below the mouth of the female body, so as to provide a location to at least partially receive the first dosage of active material.

The walls of the female body may be formed from a wide variety of materials. They may be of homogenous constructions or they may be laminated. Examples of materials suitable for use in the construction of the body include polyethylene, polypropylene, poly(methylmethacrylate), polyvinyl chloride, polystyrene, polyurethanes, polytetrafluoroethylene, nylons, polyformaldehydes, polyesters, cellulose acetate and nitro cellulose.

However, a preferred construction uses an impermeable coating to cover the exterior of a body which has been formed from a water soluble material. The coating may

- 7 -

conveniently be formed by dipping the body in a solution of a material which forms a layer which is impermeable to water. Alternatively, the body might be spray-coated. A preferred class of capsule bodies are conventional hard gelatin or starch capsule bodies coated with a solution of polyvinyl chloride or a polyvinyl acetate copolymer or an ethyl cellulose solution.

If desired, the female body may be provided with a groove adjacent its mouth which co-operates with a corresponding protrusion (for example, a ridge) on the cap so as to prelock or lock the cap and body together in the manner described in the prior art. In a particularly preferred embodiment, the groove is extended so as to form a narrowed neck portion, and the cap is provided with a pre-lock protrusion (for example, a ridge) and a spaced final lock protrusion (for example a ridge), both of which engage with the neck portion during final locking of the capsule cap to the body. The term pre-lock and lock are relative terms which express the degree of difficulty involved in removing the cap from the body. A prelocked cap can be readily removed for future filling of the capsule. A locked cap is not intended to be removed. A protrusion intended for prelocking will generally not extend as far into the groove as a protrusion intended for locking the cap to the body.

Another aspect of the invention relates to a process of filling the capsule, which comprises storing caps and

- 8 -

bodies separately, introducing the second dosage into a body, inserting a male plug into a neck of the body, introducing the first dosage above the plug or into a cap, and fitting the cap over the mouth of the body.

In another embodiment, the male member is a hollow member closed at one end, whose opposite open end engages within a neck of the female body. A water swellable material is provided within the capsule which serves to disengage the female body after a predetermined time, by forcing the male member and the female body apart as the material swells in the presence of water. The swellable material inside the capsule may be an osmagent or an osmopolymer. Such an arrangement is disclosed in W092/13521. In order to allow water to enter the capsule and to contact the water-swellable material a portion of the wall of the capsule adjacent thereto is preferably semipermeable; that is to say it is permeable to the passage of water into the capsule but impermeable to release of other substances from within the capsule.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Embodiments of the present invention will now be described by way of example only in conjunction with the drawings wherein;

Figure 1 is a cross sectional elevation of a first embodiment; and

Figure 2 is a cross sectional elevation of a second

- 9 -

embodiment having prelock and locking ridges in the inside of the cap;

Figure 3 is a cross-sectional elevation of an alternative cap for the second embodiment;

Figure 4 is a cross-section of a fourth embodiment; and

Figure 5 shows drug release profiles.

The capsule shown in Figure 1 comprises a male plug 2 formed of a hydrogel material inserted in neck 4 of female body 6. The capsule is closed with a cap 8.

The cap 8 is provided with a substantially flattened top so as to accommodate a first dosage 10 in tablet form in a first volume 9, and to minimise nesting together of caps when stacked in a filling machine. The tablet 10 is retained in the cap by means of an inwardly extending annular protrusion (or series of protrusions) 13 behind which the tablet may be clipped for ease of assembly.

The second dosage of pharmaceutically active material 12 is contained within a second volume 11 in the capsule body and may be in any suitable dosage form, such as powder, granules, tablet or even liquid form. Suitable active materials for use as the first or second active material are disclosed (but not limited to) those given in WO90/09168.

The cap is formed of a water-soluble material, such as gelatin. The capsule body is formed of a water-insoluble material, which may be a water-insoluble

- 10 -

plastics material or may be a soluble material coated with a water-impermeable coating.

The capsule body is formed in conventional manner by dipping a mould into a gelatin solution and allowing to dry. The gelatin is then coated with a water-impermeable coating (e.g. by dip coating), after the capsule body has been stripped from the mould pin and trimmed to size. Alternatively, the water-impermeable coating may be applied by spray coating or vapour deposition onto the capsule body. The cap 8 is temporarily fitted over the capsule body. The pre-assembled empty capsule is then stored for later filling. During filling, the cap is removed from the capsule body. A first dosage 10 in tablet form is inserted into first volume 9 in the cap, and a second dosage 12 of a pharmaceutically active material is filled into second volume 11 of the capsule body. The hydrogel plug is then fitted into the neck of the body so that it is just recessed below the top of the neck. Finally, the cap is replaced over the mouth of the capsule body and pushed down. The cap may be sealed in place by known means e.g. by adhesive or sealing strip.

However, the preassembly step is not essential. The caps and bodies may be stored separately and fed separately to the filling machine, particularly if precautions are taken to prevent the caps nesting together and the bodies nesting together during storage and feeding in the filling machine.

- 11 -

When the capsule is administered to a patient, the aqueous environment in the gastrointestinal tract dissolves the water-soluble cap, and releases the tablet 10 which quickly dissolves thereby administering the drug in the stomach. Since the hydrogel plug is now exposed, it absorbs water and swells, before being expelled from the body after a predetermined time interval (for example 2 to 10 hours). The second pharmaceutical material is then released into the patient's gastro-intestinal tract where it can be absorbed, for example into the colon. The active material which is released into the stomach is one which is suitable for oral administration and is capable of surviving the conditions prevailing in the stomach and intestine. On the other hand, the second pharmaceutically active material is generally one which is unable to survive the stomach/intestine environment and might for example be a protein or other material which would be degraded in the upper part of gastrointestinal tract.

Alternatively a second dose of the same drug may be required at a later time or at a later site of absorption within the gastrointestinal tract.

Figure 2 shows a second embodiment which is similar to the first, except that the cap is provided with a prelock ring 20 and a lock ring 22 (in addition to the protrusion/stop 13). The capsule body is provided with a substantially cylindrical neck portion 4 and a flared mouth portion 14 into which the rings 20 and 22 may become clipped.

- 12 -

During manufacture, the cap is prelocked to the body by pressing the cap downwards until prelock ring 20 engages over flared mouth 14. When the capsule is subsequently filled, the cap is removed by the filling machinery and the tablet 10 clipped behind inwardly protruding ring 13. The capsule body is then filled with the second pharmaceutically active material 12 prior to insertion of the hydrogel plug 2. The cap with retained tablet 10 is then pushed over the mouth of the capsule body so that both prelock ring 20 and locking ring 22 clip over the flared mouth 14 of the body and lie within the cylindrical neck portion 4 of the capsule body. Protruding ring 13 acts as stop to prevent the cap being pushed too far down onto the body (as does the lower shoulder of the neck portion 4).

Figure 3 shows an alternative cap for the second embodiment in which the stop ring 13 is omitted.

Figure 4 shows a third embodiment (analogous parts having the same reference number) wherein the plug 2 is recessed below the level of the mouth 30 of the body 6 so as to provide a location 32 to receive the tablet 10. The cap and body may optionally be provided with prelock and locking rings as shown in Figures 2 or 3 to hold the cap in place, or the cap may be held on in other known manner.

#### EXAMPLE 1

A capsule as shown in Figure 2 was filled with two

- 13 -

drugs and the release profiles assessed. An 800mg tablet (diameter 6.6mm) containing 10mg promethazine hydrochloride (first drug) was placed inside the gelatin cap. 10mg of neat metoclopramide (second drug) powder was placed in the coated gelatin capsule, and the capsule closed with a hydrogel plug recessed below the level of the capsule top. The cap was placed over the capsule and locked in place. The closed capsule was then placed in water and the amount of drug released was monitored spectrophotometrically.

The capsule details and results are given in the Table.

#### EXAMPLE 2

The procedure of Example 1 was repeated except that the first drug placed in the cap was 10mg of neat metoclopramide; and the second drug in the capsule body was an 800mg tablet (diameter 6.6mm) containing 10mg promethazine hydrochloride.

The capsule details and results are given in the Table. The release profiles of the two drugs are shown in Figure 5.

- 14 -

TABLE

Example	First drug	Second Drug
	mean release time	mean release time
	hrs.	hrs.
<hr/>		
1	0.25 (86%)	2.75 (87%)
2	immediate (99%)	3.3 (101%)
<hr/>		

Plug length = 4mm

Plug diameter = 6.90mm

Plug recess = 0.50mm

Figures in brackets give the percentage of drug released.

CLAIMS

1. A controlled release capsule which comprises a male member (2) engaged within a female body (6);

the capsule including a water swellable material which swells so as to disengage the female body upon exposure of the capsule to an aqueous medium;

a cap (8) of a water soluble material being fitted over a mouth (14) of the female body and enclosing the male member such as to define a first volume (9) containing a first unit dosage (10) of a pharmaceutically active material; and

the female body and the male member defining a second volume (11) containing a second unit dosage (12) of a pharmaceutically active material.

2. A capsule according to claim 1 wherein the cap and body are provided with co-operating pre-lock means (20,4) to removably attach the cap to the body.

3. A capsule according to claim 2 wherein the co-operating pre-lock means comprises a groove (4) adjacent the mouth of the female body, and a pre-lock protrusion (20) provided on the cap which removably engages the groove for removably attaching the cap to the body.

- 16 -

4. A capsule according to claim 1 which further comprises co-operating lock means (22,4) on the cap and body for locking the cap to the body.

5. A capsule according to claim 4 wherein the co-operating lock means comprises a groove (4) adjacent the mouth of the female body, and a locking protrusion (22) provided on the cap which lockably engages the groove for removably attaching the cap to the body.

6. A capsule according to claim 1 wherein the female body comprises a narrowed neck portion (4) adjacent the mouth (14) of the body, the neck portion being narrower than the mouth and being narrower than the remainder of the body; the cap comprising a prelock protrusion (20) closer to an open end of the cap which engages into the neck portion during prelocking, and comprising a locking protrusion (22) farther from the open end of the cap which also engages into the neck portion as the cap is locked to the body.

7. A capsule cap according to claim 6 wherein the cap further comprises a stop protrusion (13) which is located farthest from the open end of the cap for preventing the cap being pushed too far onto the female body.

8. A capsule according to any preceding claim wherein the cap has a substantially flat non-spherical top portion.

- 17 -

9. A capsule according to any preceding claim wherein the cap has a thickness such that the cap is substantially unable to nest with other such caps during assembly of the capsule.

10. A capsule according to any preceding claim wherein the cap is enteric coated such that when the capsule is swallowed by a patient the cap dissolves and releases the first active material in the intestine of the patient.

11. A capsule according to any preceding claim wherein the male member is a male plug (2) and the plug is formed of said water-swellable material.

12. A capsule according to claim 11 wherein the plug is recessed below the mouth of the body to provide a location for at least partially receiving the first active material.





FIG.1

FIG.2

FIG.3

FIG.4

2 / 2



TIME (hrs)

FIG. 5

SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

Inter mal Application No  
PCT/GB 93/02271

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61J3/07

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 A61J A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,90 09168 (NATIONAL RESEARCH DEVELOPMENT CORP.) 23 August 1990 cited in the application see claim 1	1,11
A	WO,A,92 13521 (ALZA) 20 August 1992 cited in the application see abstract; figure 1	1,11
A	US,A,4 793 493 (MAKIEJ) 27 December 1988 see claim 1; figure 1	1
A	US,A,2 340 037 (ZIPPER) 25 January 1944 see column 1, line 52 - column 2, line 28; figures 1-3	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 February 1994

Date of mailing of the international search report

04 03 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Kousouretas, I

# INTERNATIONAL SEARCH REPORT

Int. onal Application No  
PCT/GB 93/02271

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP,A,0 274 345 (WARNER-LAMBERT) 13 July 1988 see abstract; figure 7 -----</p>	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. onal Application No

PCT/GB 93/02271

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9009168	23-08-90	AU-B- 629915	15-10-92
		AU-A- 5163290	05-09-90
		EP-A, B 0384646	29-08-90
		EP-A- 0458887	04-12-91
		ES-T- 2043270	16-12-93
		GB-A, B 2230442	24-10-90
		JP-T- 4505004	03-09-92
WO-A-9213521	20-08-92	AU-A- 1339492	07-09-92
		EP-A- 0569534	18-11-93
US-A-4793493	27-12-88	US-A- 4936461	26-06-90
US-A-2340037		NONE	
EP-A-0274345	13-07-88	AU-B- 603614	22-11-90
		AU-A- 8050587	19-05-88
		DE-A- 3772023	12-09-91
		JP-A- 63135174	07-06-88
		US-A- 5074426	24-12-91